FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *   Noiman Silvia 2. Date of Event Requiring Statement (Month/Day/Year) 12/19/2017 3. Issuer Name and Ticker or Trading Symbol Eloxx Pharmaceuticals, Inc. [SVOND] (Last) (First) (Middle) C/O ELOXX PHARMACEUTICALS, INC., 950 WINTER STREET, 4TH FLOOR NORTH 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief Executive Officer 5. If Amendment, Date Original Filed(Month/Day/Year) (Street) WALTHAM, MA 02451 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	  (1)	04/26/2024(2)	Common Stock	349,400 (3)	$ 0.0006 (4)	D	Â
Stock Option (Right to Buy)	  (5)	11/16/2024(2)	Common Stock	74,871 (3)	$ 0.8 (3)	D	Â
Stock Option (Right to Buy)	  (6)	01/24/2026	Common Stock	69,880 (3)	$ 1 (3)	D	Â
Stock Option (Right to Buy)	  (7)	07/16/2027	Common Stock	45,557 (3)	$ 0.96 (3)	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Noiman Silvia C/O ELOXX PHARMACEUTICALS, INC. 950 WINTER STREET, 4TH FLOOR NORTH WALTHAM, MA 02451	  X	Â	  Chief Executive Officer	Â

Signatures

/s/ Gregory Weaver, Attorney in Fact		12/29/2017
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The option vested over a 30-month period commencing on April 26, 2014 and became fully vested and exercisable as of October 26, 2016.
(2)	The expiration date is subject to extension upon certain specified events.
(3)	Exercise price and number of option shares, as applicable, have been adjusted to reflect the Issuer's 1-for-20 reverse stock split of its issued and outstanding shares of common stock effected on December 19, 2017.
(4)	The options were priced at Israeli New Shekel 0.0020. This amount reflects the U.S. dollar equivalent of the exercise price as of the transaction date using an exchange rate of 1:3.4745, as reported by Bloomberg on December 28, 2017 as of 7 a.m., Eastern Time.
(5)	The option vested over a three-year period commencing on November 16, 2014 in twelve equal quarterly installments and became fully vested and exercisable as of November 16, 2017.
(6)	The option vests over a three-year period commencing on January 24, 2016 in twelve equal quarterly installments.
(7)	The option vests over a four-year period commencing on July 16, 2017 in sixteen equal quarterly installments.
  Remarks: Exhibit 24 - Power of Attorney. Gregory Weaver, Chief Financial Officer, is signing on behalf of Dr. Silvia Noiman pursuant to a Power of Attorney dated December 15, 2017, which is attached hereto as an exhibit.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.